- Telehealth Visits
- Insurance plan information
Varun Monga, MD
He | Him | HisMedical Oncology • Sarcoma and Connective Tissue Medical Oncology- Telehealth Visits
- Insurance plan information
Varun Monga, MD
He | Him | HisMedical Oncology • Sarcoma and Connective Tissue Medical Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Varun Monga is a medical oncologist who cares for patients with bone and soft tissue growths, including tumors in connective tissue, in the digestive tract, and in joints.
As part of UCSF's early-phase experimental therapeutics program, Monga enrolls and treats patients in phase 1 clinical trials (studies evaluating promising treatments with human volunteers). He collaborates with basic scientists and other researchers to study new cancer treatment combinations. He focuses particularly on developing targeted therapies and immunotherapies to treat sarcomas.
Monga earned his medical degree at Rajiv Gandhi Medical College in India. He completed a residency in internal medicine at Rosalind Franklin University of Medicine and Science, where he served as chief resident. He completed a fellowship in hematology and medical oncology at the University of Iowa. Before joining UCSF, he worked at the University of Iowa, caring for patients and conducting research on tumors of the nervous system and sarcomas.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
- Internal Medicine, American Board of Internal Medicine
Fellowship
- Hematology - Oncology, University of Iowa Hospitals & Clinics
Residency
- Internal Medicine, Rosalind Franklin University of Medicine / Science
Degree
- MBBS, Rajiv Gandhi Medical College (Mandya)
My expertise
Specialties
Conditions
Locations
My research
Clinical trials
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including SarcomasOpens in a new window
Recruiting
Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE),…Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)Opens in a new window
Recruiting
The primary objective is to compare the primary endpoint of PFS in subjects treated with the arginine degrading enzyme ADI-PEG 20 plus Gem and Doc (ADIGemDoc)…Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasOpens in a new window
Recruiting
Will be compared between the treatment arms (doxorubicin + pembrolizumab versus [vs] doxorubicin alone). The comparison of PFS between treatment arms will be…
Publications
Showing 1-6 of 44 reviews
- January 27, 20265 out of 5 Stars
Dr Monga has exceptional skills in communicating test results and explaining outcome potentials. He also responds in human terms to questions about likely outcomes. Diane T in reception is phenomenal in listening and relating to personal interests.
- November 22, 20255 out of 5 Stars
Dr. Monga has been excellent in all categories. He shows us the screen when explaining my chest area, he listens to our questions, he explains everything in detail. He is kind, helpful, extremely knowledgeable, smiles, engages, has fine interpersonal skills - which some MDs do not have.
- October 20, 20255 out of 5 Stars
All excellent
- October 13, 20255 out of 5 Stars
Personal and caring; explained CT and MRI results.
- September 5, 20255 out of 5 Stars
Dr. Shah was excellent to consult with !
- August 27, 20255 out of 5 Stars
Dr. Monga is friendly, professional and helpful, as is his staff.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.